Prostate cancer

• A Phase I/II Study of Neoadjuvant, Intra-arterial Administration of [177Lu]Lu-PSMA-617 in Subjects with High-risk, Localised or Locally Adva … Recruiting
  2022-500838-28-00 9 2024-09-10 "high-risk localized or locally advanced prostate cancer"
• Safety and diagnostic performance of uPAR PET imaging in localised, untreated prostate cancer. Recruiting
  2023-507111-35-00 9 2024-06-03 "Prostate Cancer"
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CD … Recruiting
  2023-506888-34-00 1 2024-05-22 "Advanced or metastatic solid tumors including hormone recept"
• Study of AZD9574 as monotherapy and in combination with anti-cancer agents in patients with advanced solid malignancies Recruiting
  2023-504984-17-00 7 2022-10-05 "Module 3: advanced/relapsed HER2-negative breast, ovarian, p"
• EXTENSION STUDY FOR PATIENTS WHO HAVE COMPLETED A PRIOR GLAXOSMITHKLINE/TESARO-SPONSORED NIRAPARIB STUDY AND ARE JUDGED BY THE INVESTIGATOR … Recruiting
  2023-506618-29-00 4 2021-09-22 "Advanced ovarian, breast, or prostate cancer"
• Roll Over Study for Patients Who Have Completed a Previous Oncology Study with Olaparib Recruiting
  2024-512982-15-00 5 2021-06-28 "BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian can"
• Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Progressive Metastatic Castration- … Recruitment ended
  2024-513968-25-00 5 2025-04-28 "Metastatic castration-resistant prostate cancer (mCRPC)"
• AD ASTRA (Androgen Deprivation with Apalutamide and STereotactic RAdiotherapy) Recruitment ended
  2024-517901-97-00 4 2023-06-13 "Localized or a locally advanced high-risk prostate cancer"
• A trial to learn how well capivasertib with docetaxel works and how safe it is in people with metastatic castration-resistant prostate cance … Recruitment ended
  2023-504996-26-00 5 2022-07-21 "Metastatic Castration Resistant Prostate Cancer (mCRPC)"
• An International, Randomized, Double-Blind, Phase III Study of Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Pl … Recruitment ended
  2023-509396-16-00 5 2021-11-08 "Metastatic Castration-Resistant Prostate Cancer"
• DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 dou … Recruitment ended
  2024-514565-18-00 5 2021-07-20 "Localised Very High-Risk Cancer of the Prostate"
• Study with apalutamide in patients with prostate cancer in whom the prostate has been removed who are at high risk of disease recurrence Recruitment ended
  2024-511832-29-00 4 2020-08-05 "High risk adenocarcinoma of the prostate after radical prost"
• A clinical study evaluating the benefits of apalutamide, a novel drug targeting prostate cancer growth, in combination with radiotherapy and … Recruitment ended
  2024-514829-36-00 5 2019-12-02 "High-risk biochemically-relapsed prostate adenocarcinoma fol"
• A research study to compare the standard treatment and the study drug (degarelix) in combination with radiotherapy in patients with high-ris … Recruitment ended
  2024-513450-30-00 5 2017-09-25 "very high risk localized or locally advanced prostate cancer"
• An international study to evaluate the safety and effectiveness of enzalutamide plus leuprolide, enzalutamide alone, and leuprolide alone in … Recruitment ended
  2024-513521-23-00 5 2015-08-19 "Prostate Cancer"
• Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: ENZAMET Recruitment ended
  2024-516137-13-00 5 2014-12-18 "Metastatic Prostate Cancer"
• A large-scale comparative study evaluating an intravenous treatment, cabazitaxel, and radiation therapy to the pelvic lymph nodes in patient … Recruitment ended
  2024-517622-25-00 5 2013-12-06 "Patients with localized prostate cancer and high-risk featur"
• A Phase 1b Study of Neoadjuvant Xaluritamig in Subjects With Newly Diagnosed Localized Intermediate or High-Risk Prostate Cancer Halted
  2024-511965-13-00 3 2024-11-25 "Newly diagnosed localized Intermediate or High‐Risk Prostate"
• Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostat … Ended
  2024-514808-13-00 5 2015-03-06 "Localised prostate cancer at high risk of recurrence"
• Effect of Copper CU64 PSMA I&T scanning to detect potential disease spread to lymph nodes in men with newly diagnosed Prostate Cancer Ended
  2024-512754-16-01 5

Showing 25–44 of 44 trials